Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gap Between NHI Prices and Market Prices Widening to about 7%
July 9, 2001
- Package Insert Drafting Guidebook for Medical Devices Issued
July 9, 2001
- Kasamatsu Meiki, Hokuho Iyaku Tie Up in Hokuriku
July 9, 2001
- Rocornal Has Secondary Preventive Effects on CAD: J-MIC (M) Study
July 9, 2001
- Contract MRs to Increase from 1,500 to 2,600 Next Year: Quintiles Seminar
July 9, 2001
- Daiichi to Apply for Prevention of Recurrent Stroke for Coversyl
July 9, 2001
- Yutaka Pharmacy Acquires Local Drugstores in Aichi
July 9, 2001
- Determination of Anti-acid-fast Bacteria Antibody Covered by Insurance
July 9, 2001
- REGULATORY NEWS IN BRIEF -2-
July 9, 2001
- 4,310 ADRs Reported by Monitor Pharmacies in Tokyo in 10 Years
July 9, 2001
- REGULATORY NEWS IN BRIEF -1-
July 9, 2001
- CORPORATE ROUNDUP
July 2, 2001
- Aventis Aiming to Achieve Highest Growth Rate in Japan: President Loescher
July 2, 2001
- Council for Regulatory Reform to Focus on Medical Fees, NHI Prices
July 2, 2001
- Blopress, Nu-lotan Up Remarkably, But Mevalotin, Lipovas Down: Top 100 Products
July 2, 2001
- 48 New Active Ingredients Approved in FY2000
July 2, 2001
- Otsuka to Acquire Meretek of the US
July 2, 2001
- Takeda's Ixense for ED Launched in France, Germany
July 2, 2001
- MEDICAL DEVICE NEWS IN BRIEF
July 2, 2001
- Kyowa Hakko to Sell Mohan to Merck Hoei
July 2, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…